Answers are grounded in this paper and cite their sources.
Selecting a polymer nanoparticle solely for tumour accumulation can ignore competing liver uptake. We quantify the relationship between these ranking objectives using paired whole-organ biodistribution measure-ments from the publicly archived Nano-Tumor Database. The primary cohort contains 142 source-labelled Polymeric formulations in 72 connected publication-reference groups, evaluated at 24 hours without temporal extrapolation. Analyses include publication-cluster bootstrap intervals, within-publication active/passive con-trasts, fixed baseline prediction models and prespecified time/material sensitivity analyses. Median tumour and liver accumulation were 0.625%ID and 9.750%ID. Tumour accumulation and the tumour/liver ratio had Spearman correlation 0.561 (publication-bootstrap 95% interval 0.396 to 0.707); only 47.2% of the top-quartile formulations overlapped between objectives. The equal-weight within-publication active/passive log10-ratio contrast was 0.209 (0.091 to 0.325) across 15 overlapping publication groups. Additional objective-weight, publication-omission and capacity ablations preserve the primary cohort. Leave-one-group-out within-publication contrasts range from 0.183 to 0.244 log10 units. The observational contrast remains confounded, and organ selectivity is not a validated safety or efficacy end-point.
No takes yet. Share an insight, caveat, or question.
Shereen Anand (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: